Q2 EPS Forecast for Moleculin Biotech Decreased by Analyst

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Stock analysts at HC Wainwright lowered their Q2 2026 EPS estimates for Moleculin Biotech in a research report issued on Friday, May 15th. HC Wainwright analyst S. Nik now expects that the company will earn ($1.65) per share for the quarter, down from their previous estimate of ($1.40). HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($4.89) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($4.60) EPS.

MBRX has been the subject of several other reports. Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Stock Performance

MBRX stock opened at $2.09 on Tuesday. The firm has a market cap of $11.16 million, a price-to-earnings ratio of -0.06 and a beta of 1.74. The firm has a 50-day simple moving average of $2.33 and a two-hundred day simple moving average of $4.60. Moleculin Biotech has a one year low of $1.79 and a one year high of $25.00.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing the consensus estimate of ($2.33) by ($1.21).

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.